Sponsored by:

Molecular Imaging

PET/CT outperforms MRI after focal therapy for prostate cancer
By Will Morton
No accurate noninvasive method has been validated to evaluate treatment response after focal therapy.
August 20, 2026
True-positive PSMA-PET with positive MRI in 74-year-old male with prostate cancer (Gleason score of 4 + 5; left anterior and posterior apex positive cores). (A) Left posterior peripheral apical to midprostate hyposignal visible on transaxial MRI. (B) No definite CT correlate evident (white arrow). (C) Focal high PSMA expression detectable in left posterior mid to base with SUVmax of 12.4 on transaxial fused delayed pelvic PET/CT (yellow arrow). (D) Focal high PSMA expression found in left midgland to base of prostate on maximum-intensity-projection image (yellow arrow).
Cortechs.ai wins FDA clearance for NeuroQuant PET
By AuntMinnie.com staff writers
The software offers automated quantification for amyloid PET imaging in Alzheimer's disease and other neurological conditions.
August 19, 2026
A Ibrain
Norroy secures FDA breakthrough therapy, fast track status for PET imaging agent
By AuntMinnie.com staff writers
Norroy said Ga-68 NYM096 is the first China-originated radiopharmaceutical to receive FDA breakthrough therapy designation.
August 19, 2026
Kidney
IU Health launches theranostics center
By AuntMinnie.com staff writers
The center is supported by a $40 million commitment.
August 19, 2026
Nuclearmedicine
New immuno-PET tracer shows promise in lung cancer
By Will Morton
Molecular imaging can provide whole-body visualization and quantitative assessment of PD-L1 expression.
August 18, 2026
(A) Ga-68 NK224 PET/CT maximum intensity projection image (left), axial PET/CT images (center), and axial CT images (right) in a 43-year-old female participant with lung adenocarcinoma show lesions in the right cerebellum (blue arrow), right frontal lobe (red arrow), and sternum (green arrow) with low, intermediate, and high tracer uptake, respectively. Photomicrographs (scale bar, 100 μm) with hematoxylin-eosin (H&E) staining (center bottom) and programmed death ligand 1 (PD-L1) immunohistochemical (IHC) staining (right bottom) show high PD-L1 expression in the sternal lesion (tumor proportion score ≥ 50%).
Lantheus wins FDA approval for tau PET imaging agent
By AuntMinnie.com staff writers
Tauklarify, previously known as MK-6240, has been approved for tau PET imaging in adults with cognitive impairment being evaluated for Alzheimer's disease.
August 14, 2026
Approved Stamp 400
FAPI-PET/CT shows promise in hepatopancreatobiliary cancers
By Will Morton
FAPI-PET/CT could potentially improve noninvasive cancer staging, and, ultimately, clinical decision making.
August 13, 2026
Shown is a 69-year-old man with a cholangiocarcinoma in the distal common bile duct. F-18 FDG-PET/CT was negative where Ga-68 FAPI-46 PET/CT showed high focal FAPI uptake in the liver hilum and surrounding lymph nodes. a-d: F-18 FDG-PET/CT, e-h: Ga-68 FAPI-46 PET/CT. a, b, e, f: Maximum intensity projections, c, g: axial fusion images, d, h: non-contrast enhanced CT.
Radnostix reports revenue decline in Q2
By AuntMinnie.com staff writers
The company attributed the revenue dip to two voluntary product recalls and the Cobalt-60 hot-cell shutdown.
August 13, 2026
Research Money 400
PET/CT predicts response to neoadjuvant therapy in breast cancer
By Will Morton
Monitoring neoadjuvant therapy response in HER2-positive breast cancer is challenging with existing tools.
August 11, 2026
Ga-68 HER2-PET/CT images before neoadjuvant therapy, at end of second cycle, and before surgery. (A) Baseline scan demonstrated soft-tissue lesion measuring approximately 2.3 × 2.2 cm in upper outer quadrant of left breast, with marked radiotracer uptake and SUVmax of 10.1. (B) At end of second cycle, imaging revealed residual lesion of approximately 2.2 × 1.0 cm in same region, without abnormal radiotracer accumulation. (C) Preoperative imaging demonstrated further reduction in lesion size to approximately 2.0 × 0.6 cm, with no abnormal tracer uptake detected.
ITM receives Complete Response Letter for ITM-11
By AuntMinnie.com staff writers
The FDA stated that it's unable to approve the NDA in its present form.
August 10, 2026
Nuclear Medicine
Lantheus reports increased Q2 revenue following Curium deal
By AuntMinnie.com staff writers
The company reported a 2.7% revenue increase in the second quarter of 2026 compared to the same period in 2025.
August 6, 2026
Stock Exchange 400
Plus Therapeutics rebrands as Cerenome
By AuntMinnie.com staff writers
The move reflects the company's evolution from a therapeutics-focused organization into an integrated central nervous system (CNS) oncology company.
August 3, 2026
Cerenome
Page 1 of 633
Next Page